Recently Viewed
Clear All
$76 Mln
--
0.82
--
0.02
-0.62 %
--
0 %
--
-1.48
$-163.35 Mln
$-222.37 Mln
$-258.98 Mln
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
---|---|---|---|---|---|---|---|
VistaGen Therapeutics (VTGN)
| 0.68 | 1.37 | 5.32 | -39.39 | -59.59 | -32.54 | -32.44 |
BSE Sensex
| -2.95 | -0.51 | -2.25 | 6.13 | 9.30 | 12.87 | 10.07 |
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
---|---|---|---|---|---|---|---|
VistaGen Therapeutics (VTGN)
| -42.35 | 66.34 | -94.87 | 0.52 | 181.28 | -54.02 | 34.50 |
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
--
--Min --Median --Max
--
--Min --Median --Max
--
Earnings Yield (%) = EBIT / Enterprise value
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
---|---|---|---|---|
65.94 | 10,803.69 | 70.25 | 7.61 | |
32.99 | 11,902.42 | -- | -17.98 | |
115.02 | 11,683.26 | 35.51 | 15.12 | |
84.00 | 10,646.49 | -- | -18.8 |
Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company's product pipeline comprises PH94B, a fasedienol nasal spray, which is in... Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women's health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. Address: 343 Allerton Avenue, South San Francisco, CA, United States, 94080 Read more
Mr. Shawn K. Singh J.D.
Mr. Shawn K. Singh J.D.
South San Francisco, CA
The total asset value of VistaGen Therapeutics Inc (VTGN) stood at $ 110 Mln as on 30-Sep-24
The share price of VistaGen Therapeutics Inc (VTGN) is $2.97 (NASDAQ) as of 14-Feb-2025 16:04 EST. VistaGen Therapeutics Inc (VTGN) has given a return of -59.59% in the last 3 years.
VistaGen Therapeutics Inc (VTGN) has a market capitalisation of $ 76 Mln as on 13-Feb-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of VistaGen Therapeutics Inc (VTGN) is 0.82 times as on 13-Feb-2025, a 71% discount to its peers’ median range of 2.78 times.
Since, TTM earnings of VistaGen Therapeutics Inc (VTGN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the VistaGen Therapeutics Inc (VTGN) and enter the required number of quantities and click on buy to purchase the shares of VistaGen Therapeutics Inc (VTGN).
Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company's product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women's health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. Address: 343 Allerton Avenue, South San Francisco, CA, United States, 94080
The CEO & director of Mr. Shawn K. Singh J.D.. is VistaGen Therapeutics Inc (VTGN), and CFO & Sr. VP is Mr. Shawn K. Singh J.D..
There is no promoter pledging in VistaGen Therapeutics Inc (VTGN).
Some of the close peers are:
Company | Market Cap($ Mln) |
---|---|
1,190
|
|
1,168
|
|
1,080
|
|
1,065
|
VistaGen Therapeutics Inc. (VTGN) | Ratios |
---|---|
Return on equity(%)
|
-38.18
|
Operating margin(%)
|
-5207.43
|
Net Margin(%)
|
-4518.12
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of VistaGen Therapeutics Inc (VTGN) was $0 Mln.